Lotus revenue hits record on exports By Kao Shih-ching / Staff reporter Lotus Pharmaceutical Co (美時化學製藥), one of the nation’s leading specialty generic drug developers, yesterday said revenue last year hit a record NT$10.58 billion (US$371.4 million) on the back of robust exports. Revenue last year rose 15 percent annually, despite plummeting 41.7 percent last month to NT$1.01 billion, which could be attributed to a high comparison base in 2019 due to higher sales of gSuboxone, a company official said by telephone. GSuboxone is the generic version of Indivior Inc’s Suboxone used in the treatment of opioid use disorder, company data showed. “Although falling annually, December’s revenue still stood at a comparatively high level. It was the fifth month with revenue of more than NT$1 billion last year,” Lotus Pharmaceutical director of corporate finance and investor relations Angela Luan (欒君儀) said.